NURTEC ODT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NURTEC ODT (NURTEC ODT).
CGRP receptor antagonist; blocks binding of calcitonin gene-related peptide to its receptor, inhibiting vasodilation and neurogenic inflammation in trigeminovascular system.
| Metabolism | Primarily metabolized by CYP3A4; also by CYP2C9 (minor). |
| Excretion | Roughly 75% of dose excreted in feces (as unchanged drug and metabolites), 24% in urine (mostly metabolites, <1% unchanged). |
| Half-life | Terminal elimination half-life of approximately 11 hours, supporting twice-daily dosing for migraine prevention. |
| Protein binding | Approximately 88% bound to human serum albumin. |
| Volume of Distribution | Approximately 120 L, suggesting extensive tissue distribution (not weight-normalized, corresponds to ~1.5 L/kg for 80 kg individual). |
| Bioavailability | Oral bioavailability is approximately 100% following ODT administration, with no significant food effect. |
| Onset of Action | Onset of headache relief observed as early as 60 minutes after oral administration for acute migraine treatment. |
| Duration of Action | Duration of action approximately 24 hours, supporting daily dosing for prevention; for acute treatment, single dose provides relief for up to 48 hours in some patients. |
75 mg orally once daily as needed, not to exceed 75 mg in 24 hours.
| Dosage form | TABLET, ORALLY DISINTEGRATING |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min/1.73 m²). Not recommended for severe renal impairment (eGFR <30 mL/min/1.73 m²) due to lack of data. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not recommended for moderate to severe hepatic impairment (Child-Pugh B or C) due to lack of data. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended; limited data in patients ≥65 years but no evidence of altered pharmacokinetics. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NURTEC ODT (NURTEC ODT).
| Breastfeeding | No data on presence in human milk; potential for serious adverse reactions in breastfed infants; M/P ratio not established. |
| Teratogenic Risk | No human data available; animal studies show no evidence of fetal harm at exposures up to 3 times the human exposure. First trimester: insufficient data to determine risk. Second and third trimesters: no known teratogenicity. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
["History of hypersensitivity to rimegepant or any excipient","Concurrent use with strong CYP3A4 inhibitors (for doses exceeding 75 mg per dose; see dosing)"]
| Precautions | ["Hypersensitivity reactions including angioedema and dyspnea","Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) increases rimegepant exposure; reduce dose","Concomitant use with strong CYP3A4 inducers (e.g., rifampin, phenytoin) may reduce efficacy","Pregnancy: limited data; avoid use unless potential benefit outweighs risk","Lactation: unknown if excreted in breast milk; consider risk/benefit"] |
Loading safety data…
| No specific monitoring required; routine pregnancy monitoring is recommended. |
| Fertility Effects | No adverse effects on fertility observed in animal studies; human data lacking. |